Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
